title: In vitro-in vivo study of CoQ10-loaded lipid nanoparticles in comparison with nanocrystals.
abstract: The present work described the effect of CoQ10 dissolution characteristics in nanocrystals and lipid nanoparticles (LNs) on its oral absorption in rats. Nanocrystals and LNs were prepared by melt-high pressure homogenization and sucrose monolaurate was used as a stabilizer in all formulations. Witepsol(®)W35 and medium-chain triglycerides (MCT) were selected as lipid additives to form LN(CoQ10+W35) and LN(CoQ10+MCT), respectively. From the results obtained, the particle size of CoQ10 nanocrystals was 285 nm, while it was reduced to 150 nm by mixture with an equal amount of lipid additives due to their lower melting points. In vitro dissolution results indicated that the drug release from two LNs was delayed compared with that from nanocrystals, and LN(CoQ10+W35) exhibited the highest drug release over 4h. Finally, in vivo evaluation demonstrated that the oral absorption of CoQ10 was markedly increased by using nanocrystals and LNs compared with a coarse suspension. A good relationship was found between the in vitro dissolution and in vivo evaluation. The enhanced oral absorption of CoQ10 by nanocrystals and LNs was due to improved dissolution. In conclusion, Witepsol(®)W35 was shown to be a better lipid additive for the preparation of LNs to increase the oral absorption of CoQ10.
authors.affiliation: Department of Pharmaceutics, School of Pharmaceutical Science, Shenyang Pharmaceutical University, No. 103, Wenhua Road, Shenyang 110016, China.
authors.forename: Hongyu
authors.initials: H
authors.lastname: Piao
authors.forename: Mei
authors.initials: M
authors.lastname: Ouyang
authors.forename: Dengning
authors.initials: D
authors.lastname: Xia
authors.forename: Peng
authors.initials: P
authors.lastname: Quan
authors.forename: Wenhua
authors.initials: W
authors.lastname: Xiao
authors.forename: Yanzhi
authors.initials: Y
authors.lastname: Song
authors.forename: Fude
authors.initials: F
authors.lastname: Cui
mesh_terms: D000284:Administration, Oral; D000818:Animals; D005079:Excipients / Q000737:chemistry*; D008055:Lipids / Q000737:chemistry; D008297:Male; D053758:Nanoparticles; D010316:Particle Size; D051381:Rats; D017208:Rats, Wistar; D012995:Solubility; D013395:Sucrose / Q000031:analogs & derivatives* / Q000737:chemistry; D014280:Triglycerides / Q000737:chemistry; D014451:Ubiquinone / Q000008:administration & dosage / Q000031:analogs & derivatives*
chemical_list: D005079:Excipients; D008055:Lipids; D014280:Triglycerides; C018152:sucrose monolaurate; C009683:witepsol; D014451:Ubiquinone; D013395:Sucrose; C024989:coenzyme Q10